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Abstract  60	  
 61	  
Background 62	  
Long-term toxicities from current treatments are a major issue in pediatric cancer. 63	  
Previous studies, including our own, have shown prognostic value for the 64	  
presence of PAX3/7-FOXO1 fusion genes in rhabdomyosarcoma.  It is proposed 65	  
to introduce PAX3/7-FOXO1 positivity as a component of risk stratification, rather 66	  
than alveolar histology, in future clinical trials. 67	  
Procedure 68	  
To assess the potential impact of this reclassification, we have determined the 69	  
changes to risk category assignment of 210 histologically reviewed patients 70	  
treated in the UK from previous MMT (Malignant Mesenchymal Tumor) clinical 71	  
trials for non-metastatic rhabdomyosarcoma based on identification of PAX3/7-72	  
FOXO1 by fluorescence in situ hybridization and/or reverse transcription PCR. 73	  
Results 74	  
Using fusion gene positivity in the current risk stratification would re-assign 7% of 75	  
patients to different EpSSG (European Paediatric Soft Tissue Sarcoma Study 76	  
Group) risk subgroups. The next European trial would have 80% power to detect 77	  
differences in event free survival of 15% over 10 years and 20% over 5 years in 78	  
reassigned patients.  This would decrease treatment for over a quarter of patients 79	  
with alveolar histology tumors that lack PAX3/7-FOXO1. 80	  
Conclusions 81	  
Fusion gene status used in stratification may result in significant numbers of 82	  
patients benefitting from lower treatment associated toxicity. Prospective testing 83	  
to show this reassignment maintains current survival rates is now required and is 84	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shown to be feasible based on estimated recruitment to a future EpSSG trial. 85	  
Together with developing novel therapeutic strategies for patients identified as 86	  
higher risk, this may ultimately improve the outcome and quality of life for patients 87	  
with rhabdomyosarcoma.    88	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Introduction 89	  
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, 90	  
with ~450 children and adolescents newly diagnosed each year in Europe 91	  
(countries which report data to the Automated Childhood Cancer Information 92	  
System, ACCIS1,2). The substantial improvement in survival rate for RMS patients 93	  
that occurred from 1960 to 1996 with the advent of chemotherapeutic agents has 94	  
largely stagnated with an estimated 5 year survival rate of 72%3,4. The reality 95	  
remains that while the majority of children suffering from cancer will survive to 96	  
adulthood, more than 80% of these will develop a serious or life threatening 97	  
chronic health condition by the age of 45 as a result of their curative treatment5. 98	  
Accurate risk determination in RMS patients is a priority to enable safe reduction 99	  
of treatment intensity for those at lower risk and identify those at highest risk of 100	  
succumbing to their disease who could benefit from treatment intensification 101	  
and/or novel therapeutic strategies.   102	  
 103	  
Current clinical trials for RMS in Europe and the US use histological subtype 104	  
alongside other clinical parameters including age at diagnosis, site and size of 105	  
primary tumour, extent of residual disease after surgery, node involvement, and 106	  
metastases to allocate patients to a risk group which will determine treatment 107	  
intensity 6. Two main histological subtypes are recognised, embryonal (ERMS) 108	  
which typically has a better prognosis than the alveolar (ARMS) “unfavourable 109	  
histology” subtype.  The majority (70-80%) of ARMS cases have translocations 110	  
resulting in fusion of the PAX3 or PAX7 gene with FOXO1 7,8. The resultant fusion 111	  
proteins are novel transcription factors and considered key drivers of 112	  
tumorigenesis9. 113	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 114	  
Previous studies including large-scale expression profiling have revealed that 115	  
ARMS tumours lacking characteristic fusion genes are molecularly and clinically 116	  
indistinguishable from ERMS tumors10,11. This is consistent with several studies, 117	  
including a recent prospective assessment, that show a prognostic value for the 118	  
fusion genes 12–15 although some issues with the representativeness of sample 119	  
cohorts are also reported16,17. Based on the consensus view from these studies, 120	  
that fusion gene presence rather than alveolar histology per se contributes to 121	  
poorer outcome, it is proposed to incorporate fusion-gene status, rather than 122	  
histology, into risk stratification of RMS. In order to address the impact of such a 123	  
change in non-metastatic patients, we used the current EpSSG RMS2005 trial 124	  
framework for risk stratification and applied this to a large cohort of well-125	  
annotated RMS cases enrolled in the series of Malignant Mesenchymal Tumour 126	  
(MMT) trials, which we subjected to histopathological re-review. The treatment 127	  
and outcome for patients in these trials were similar 18,19 and therefore were 128	  
considered suitable for analysis as a single cohort.   129	  
 130	  
Here we report the impact of adopting fusion gene status in place of histology as 131	  
part of RMS risk stratification. This has allowed us to estimate the proportion of 132	  
patients that would change risk group and the power of future clinical trials to 133	  
assess any adverse changes in patient outcome.  134	  
 135	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Materials and Methods 136	  
Pathology and tissue microarray construction 137	  
Formalin fixed paraffin embedded (FFPE) samples from UK patients enrolled on 138	  
the MMT89, MMT95 and MMT98 trials from the International Society of Paediatric 139	  
Oncology (SIOP) were collected from multiple UK centres (Local Research Ethics 140	  
Committee protocol 1836 and Multi-Regional Research Ethics 141	  
Committee/98/4/023). Our cohort was subjected to histological re-review (A.K.) to 142	  
apply current histological classification criteria20. Cases with mixed histologies but 143	  
containing true alveolar histology (classical and solid variant patterns) were 144	  
considered to be ARMS. Clinical parameters were accessed from trial 145	  
databases21. These and updated histological subtypes of samples from cases 146	  
non-metastatic at diagnoses (stage I-III) are summarised in Table 1, and were 147	  
representative of other RMS cohorts12. A smaller cohort of metastatic cases 148	  
(summarised in Supplemental Table S1) was used separately for additional 149	  
analyses. Moreover, outcomes from MMT89 and MMT95 cases used in this study 150	  
were representative of their respective trials (MMT89; Overall survival (OS) 151	  
74.4%, Event Free survival (EFS) 62.6%, MMT95; OS 74.3%, EFS 64% at 5 152	  
years)18,19 (Outcome data shown refers to the cohort used in this study). The 153	  
histopathologic diagnoses of the cases studied are also considered largely 154	  
representative of the cases on the MMT89, MMT95 and MMT98 trials. 155	  
 156	  
Haematoxylin and eosin stained slides were marked for regions of tumour and a 157	  
tissue microarray (TMA) constructed containing 1,863 cores representing RMS 158	  
tumour from 329 patients. This involved taking 0.6mm cores from tumour-159	  
containing regions of donor blocks and insertion into a recipient array block. 160	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There was an average of 6 cores per sample (range 1-24).  RMS cell lines 161	  
negative and positive for each fusion gene (RD (negative)22, RH30 (PAX3-162	  
FOXO1)23, RMZ-RC2 (PAX7-FOXO1)24) were formalin fixed, paraffin embedded 163	  
and cores inserted into each array block to act as controls. Sources and culturing 164	  
conditions for cell lines have been previously described 25. 165	  
 166	  
Fusion gene status assessment by fluorescence in situ hybridisation 167	  
Fluorescence in situ hybridisation (FISH) was performed on the TMA slides to 168	  
determine whether samples carried a PAX3-FOXO1 or PAX7-FOXO1 fusion gene 169	  
or neither.  Bacterial artificial chromosome (BAC) DNA probes were identified that 170	  
hybridize to the 5’ end of PAX3 and PAX7 and to the 3’end of FOXO1. BAC DNA 171	  
was amplified and subsequently purified using the Genomiphi Kit (GE Healthcare, 172	  
Little Chalfont, Buckinghamshire, UK) according to manufacturers instructions. 173	  
BACs used for PAX3 were RP11-81I8, RP11-16P6 and RP11-612G6 (labelled 174	  
with Digoxygenin (DIG) (Roche, Basel, Switzerland) by random priming and 175	  
indirectly detected using fluorescein isothiocyanate (FITC)-conjugated anti-DIG 176	  
antibodies (Thermo Fisher Scientific, Waltham, MA, USA)). BACs used for PAX7 177	  
were RP11-468NG, CTD-2009F7 and RP11-121A23 (directly labelled using 178	  
FISHBright® Aqua and the FISHBright® Nucleic Acid Labelling Kit (Leica 179	  
Microsystems, Wetzlar, Germany)) and BACs used for FOXO1 were RP11-180	  
452K11, RP11-805F18 and RP11-350A18 (labelled with biotin by random priming 181	  
and indirectly detected using Cy3-conjugated Streptavidin (Thermo Fisher 182	  
Scientific)). All labelled BACs were individually hybridized to normal metaphase 183	  
chromosomes to ensure their correct chromosomal location. FISH was carried out 184	  
on TMA sections as previously described26. Slides were scanned using an Ariol 185	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slide scanner (SL-50) (Leica Microsystems) and each core was independently 186	  
scored for fused red/green and red/aqua signals in a minimum of 50 non-187	  
overlapping tumour nuclei by 2 independent observers. Fused signals, less than 188	  
a signal width apart, were required to be present in at least 10% of scorable 189	  
nuclei for a core to be considered fusion gene positive. 190	  
 191	  
Fusion gene status assessment by reverse transcription-PCR 192	  
In addition to preparing TMAs, we also cut 10-micron FFPE sections for a subset 193	  
of samples where sufficient material was available.  These were assessed for 194	  
fusion gene status by reverse transcription (RT)-PCR. RT-PCR results were used 195	  
to confirm FISH results or provide a result in the event that FISH hybridisation for 196	  
a patient was not successful. RNA was extracted from the FFPE rolls using the 197	  
RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific) 198	  
according to manufacturers’ instructions. Reverse transcription was subsequently 199	  
carried out on up to 1 mg of total RNA using the High Capacity Reverse 200	  
Transcription Kit (Thermo Fisher Scientific). cDNA was then amplified in triplicate 201	  
by real-time quantitative RT-PCR using Taqman  (Thermo Fisher Scientific) 202	  
reagents for PAX3-FOXO1, PAX7-FOXO1 and Beta-2-microglobulin (B2M) 203	  
expression, the latter acting as a reference gene. The primer sequences used in 204	  
these assays have been previously described 27. Each assay was performed 205	  
separately and cDNA from control cell lines (as indicated above) (no fusion gene, 206	  
PAX3-FOXO- and PAX7-FOXO1-positive) was included in each run. Samples 207	  
were designated fusion gene positive if amplification occurred for the relevant 208	  
assay whereas samples were only designated fusion gene negative if no 209	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amplification was seen for either fusion gene assay and the signal from the B2M 210	  
assay was not reached in less than or equal to 30 cycles. 211	  
 212	  
Survival analysis was evaluated using the Mantel-Cox log rank test, Mantel-213	  
Haenszel Hazard Ratio and Kaplan-Meier plots. 214	  
 215	  
Results 216	  
Ascertainment of fusion gene status in TMA cohort 217	  
Using FISH and/or RT-PCR analysis, fusion gene status was successfully 218	  
determined in 210 patients with non-metastatic disease and a smaller cohort of 219	  
50 patients with metastasis that were treated on MMT clinical trials and had full 220	  
clinical follow up data. 155 samples were assigned using FISH results only, 17 221	  
using PCR results only and 88 were assigned using both methods with complete 222	  
concordance. The results are included in Table 2. We identified one patient 223	  
described as having embryonal histology yet was found to harbour a PAX3-224	  
FOXO1 fusion gene (0.64% of all ERMS patients). 20 patients with ARMS 225	  
histology were found to be fusion gene negative (37.7% of all ARMS patients), 5 226	  
of which had mixed histology with only areas of true alveolar histology20.  227	  
 228	  
Comparison between risk determined using histology or molecular fusion 229	  
gene status 230	  
Within the non-metastatic setting, Kaplan-Meier analysis demonstrated that there 231	  
was no significant difference in overall (OS) or event free survival (EFS) between 232	  
patients with ERMS and fusion negative ARMS in contrast to the fusion positive 233	  
cases that showed a significantly poorer overall survival outcome than fusion 234	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negative (log rank test, chi square value 21.9, p<0.0001, HR 6.047 (95% CI 235	  
2.845-2.85)) (Fig 1).  This is consistent with previous studies, including our 236	  
own11,12. The Kaplan-Meier plots for fusion positive cases divided into PAX3-237	  
FOXO1 and PAX7-FOXO1 (Supplemental Fig S1) shows no significant difference 238	  
in survival between PAX7-FOXO1 cases and any other subgroup, although the 239	  
numbers are low. In the metastatic cohort, the outcome of patients with fusion 240	  
negative alveolar disease appeared to be as poor as fusion positive cases 241	  
(Supplemental Fig S2a) although there is no statistical significance between 242	  
ERMS and fusion negative ARMS groups, but the numbers of these metastatic 243	  
cases are very low. We also assessed outcome of our non-metastatic cohort 244	  
according to the current non-metastatic EpSSG risk groups (Supplemental Table 245	  
S2, treatment protocol associated with risk groups is outlined in Supplemental 246	  
Table S3) and showed that the survival rates for each risk group were as 247	  
expected (Supplemental Fig S2b).   248	  
 249	  
In order to assess the impact of using fusion status rather than histology on 250	  
patient risk stratification, we stratified all patients using i) histopathology, 251	  
according to the EpSSG 2005 trial regimen using the re-reviewed histology 252	  
(ERMS as favourable, ARMS as unfavourable) and ii) fusion status in place of 253	  
histopathology (fusion negative as favourable, fusion positive as unfavourable). 254	  
The risk group of each patient from each analysis was then compared. Using 255	  
fusion gene status, 14 patients with fusion gene negative ARMS (26.4% of all 256	  
patients with ARMS, 70% of fusion negative ARMS patients) changed risk group 257	  
(5 moved from very high to high, 8 moved from high to standard, 1 moved from 258	  
high to low). A summary of these changes using fusion gene status is shown in 259	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for risk groups in Table 3 and for subgroups in Supplemental Table S4.  Note in 260	  
Supplemental Table S4, that although 6 patients changed risk subgroup from G 261	  
to E, there was no change in overall risk group (high) and therefore no change in 262	  
treatment strategy for those particular patients. These changes would result in 263	  
reducing treatment intensity for 14/20 fusion negative ARMS.  264	  
 265	  
It is vital to assess the patients receiving less intense treatment as a result of the 266	  
change in stratification in forthcoming trials to ensure that their clinical outcome is 267	  
not compromised. Assuming a null hypothesis that patients with fusion negative 268	  
ARMS with downgraded risk will have an identical EFS rate to patients with 269	  
ERMS of 70%, we performed power calculations to estimate the total patient 270	  
number needed to have 80% power to identify decreases in EFS in this group 271	  
(Table 4). Based on the previous trial, we predict that the next EpSSG trial is 272	  
expected to recruit ~125 patients with non-metastatic paediatric RMS per year. 273	  
Using the frequencies found in this study, we estimate that the next trial will have 274	  
80% power to detect differences in EFS of 15% over 7 years and 20% over 5 275	  
years. 276	  
 277	  
Discussion 278	  
Assessment of the molecular features of tumours is increasingly required for 279	  
accurate diagnoses, risk stratification and precision approaches to treatment 280	  
decisions for patients.  Previous studies, including our own, have shown a 281	  
prognostic value for the presence of the fusion gene in RMS and it is proposed to 282	  
introduce this as a molecularly unfavourable category, in place of alveolar 283	  
histology, into future clinical trials. Here, our assessment of 210 samples from 284	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previous clinical trials, that are representative of the trials as a whole, shows that 285	  
overall this would affect assignment of patients to specific risk subgroups, 286	  
reducing treatment for over a quarter of patients with alveolar histology and 7% of 287	  
all non-metastatic RMS (it is noteworthy that the next European trial plans to 288	  
intensify chemotherapy for the High and Very High risk groups, which is likely to 289	  
increase treatment associated morbidity). This has potential to reduce long-term 290	  
toxicities in these patients, which is important as such toxicities are a major issue 291	  
in the majority of RMS patients that are cured of their disease28.   292	  
 293	  
Changes in the histopathological criteria used to discriminate between embyronal 294	  
and alveolar histology have been updated over time, with the introduction in 1995 295	  
of a prognostically relevant classification system which determined that even focal 296	  
alveolar histology should confer an ARMS diagnosis29 resulting in an increasing 297	  
proportion of ARMS cases. More recently, a re-examination of these criteria noted 298	  
that certain histological patterns may be mimicking ARMS30, leading to an 299	  
artificially high rate of ARMS diagnosis. Despite our cohort being re-reviewed 300	  
using current criteria, we observed a relatively high proportion of fusion negative 301	  
ARMS (37.7%).  However, including patients with metastasis in our cohort 302	  
reduced this proportion to 26.9% similar to other studies and may reflect the more 303	  
metastatic behaviour of ARMS driven by the fusion protein 11,31. The range of 304	  
proportions of fusion negative ARMS reported is underpinned by diagnostic 305	  
uncertainty using histopathological criteria in challenging cases, where informal 306	  
use of the fusion gene status and other clinical parameters is guiding histological 307	  
diagnoses. Standardizing use of molecular criteria in future trials is therefore 308	  
highly desirable. 309	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 310	  
We identified 1 out of 157 patients with ERMS to be PAX3-FOXO1 positive by 311	  
both FISH and RT-PCR. Fusion positive ERMS cases have been reported 312	  
before27 where PCR detection was used, notably all of these cases demonstrated 313	  
diffuse myogenin staining, a feature associated with ARMS32. This suggests that 314	  
there is a rationale to screen for fusion genes in all patients, as these patients 315	  
may move from low to high-risk groups. Previous studies have reported that 316	  
patients with tumours harbouring a PAX7-FOXO1 gene have a superior outcome 317	  
compared to PAX3-FOXO111,12,33 however numbers are limited and this may be 318	  
stage-dependent13. We only had 6 patient samples with a PAX7-FOXO1 gene in 319	  
our cohort and therefore could not address this question adequately in this study. 320	  
Rarer fusion gene variants are reported such as PAX3-NCOA1 and PAX3-321	  
NCOA234 in ARMS and ERMS, however the clinical significance of these are 322	  
unclear. 323	  
 324	  
Stratifying RMS patients according to molecular rather than histopathological 325	  
criteria will result in a proportion of fusion negative alveolar patients (26.4% of 326	  
patients with ARMS in this study) receiving less intense treatment, being 327	  
perceived to be at lower risk. It is important to establish that these patients will 328	  
have a similarly favourable outcome as patients with ERMS when treated on the 329	  
same protocol. Using data from our patient population, we have estimated that 330	  
the expected number of patients recruited to the next EpSSG trial will be sufficient 331	  
to detect changes in event free survival of 15% over 7 years and 20% over 5 332	  
years with 80% power. Patients with ERMS have an EFS of 70% at 5 years 333	  
compared to fusion positive ARMS with 36.1% at 5 years. It is anticipated that 334	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molecular features of RMS will be increasingly incorporated into risk stratification 335	  
as there is evidence that MYOD1 mutations in sclerosing/spindle RMS35–37, CDK4 336	  
amplification38 and the MG5 gene signature in fusion negative RMS25,39 can all 337	  
impact survival. 338	  
 339	  
Here we have determined the potential impact of using fusion gene status rather 340	  
than the histopathological definition of alveolar histology as an adverse indicator 341	  
in the risk-stratification of RMS that is proposed for use in the next clinical trials. 342	  
We show that a significant proportion of patients with non-metastatic RMS (7%) 343	  
will be assigned to a different risk group and treatment protocol as a 344	  
consequence of this change. It is expected that this will result in children being 345	  
spared some of the considerable toxicities and late effects of intense therapy 346	  
without compromising their chance of cure, in addition to the possibility of 347	  
identifying fusion positive patients presenting with ERMS or RMS-NOS that will 348	  
benefit from being considered as high-risk. 349	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Figure Legends 498	  
Fig 1. Overall survival  (A) and event free survival (B) in non-metastatic RMS 499	  
patients grouped into ERMS fusion negative (ERMS FN), ARMS fusion negative 500	  
(ARMS FN) and fusion positive patients (FP). 501	  
 502	  
Supplemental Figure Legends 503	  
 504	  
Supplemental Figure S1. Overall survival  (A) and event free survival (B) in non-505	  
metastatic RMS patients grouped into ERMS fusion negative (ERMS FN), ARMS 506	  
fusion negative (ARMS FN), PAX3-FOXO1 and PAX7-FOXO1. 507	  
 508	  
Supplemental Figure S2. (A) Overall survival in metastatic (stage IV) RMS 509	  
grouped into ERMS fusion negative (ERMS FN), ARMS fusion negative (ARMS 510	  
FN) and fusion positive patients (FP). (B) Overall survival in non-metastatic RMS 511	  
patients stratified into risk groups according to the current EpSSG RMS2005 512	  
clinical trial criteria. 513	  
 514	  
Supplemental Table Legends 515	  
 516	  
Supplemental Table S1. Clinical and molecular characteristics of the metastatic 517	  
cohort. 518	  
 519	  
Supplemental Table S2. Risk Stratification for the EpSSG non-metastatic RMS 520	  
study. Pathology: Favourable indicates embryonal histology including botryoid 521	  
and spindle cell subtypes; Unfavourable indicates alveolar histology. Post 522	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surgical stage (IRS group): I indicates complete primary resection; II indicates 523	  
microscopic residual or primary complete resection but N1; III indicates 524	  
macroscopic residual. Site: Favourable indicates Orbit, Genitourinary (non 525	  
bladder/prostate), Head and neck (non-parameningeal); Unfavourable indicates 526	  
parameningeal, extremities, Genitourinary bladder/prostate and all other sites. 527	  
Node Stage: N0 indicates no clinical or pathological node involvement; N1 528	  
indicates pathological node involvement. Size and Age: Favourable indicates 529	  
tumour size less than or equal to 5 cm and age less than 10 years; Unfavourable 530	  
indicates all other options (i.e. Size greater than 5 cm and/or age greater than or 531	  
equal to 10 years). 532	  
 533	  
Supplemental Table S3. Treatment protocol for EpSSG RMS risk groups. Tumour 534	  
assessment carried out between first and second course of frontline therapy. VA 535	  
= Vincristine/Actinomycin;  536	  
IVA = Ifosfamide/Vincristine/Actinomycin; RT = radiotherapy; IVADo = 537	  
Ifosfamide/Vincristine/Actinomycin/Doxorubicin 538	  
*only given if patient shows complete response (CR) to first course and has 539	  
favourable age and tumour size. 540	  
**If patient shows stable disease (SD) after first course, second line treatment 541	  
(usually Carboplatin, Cyclophosphamide, Topotecan or Doxorubicin) with 542	  
radiotherapy will be given. 543	  
***Randomised trial arms. 544	  
 545	  
 546	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Supplemental Table S4. Summary of changes in subgroup between histological 547	  
and molecular categorization of pathology. Hist. = Histology; Mol. = Molecular. 548	  
Note that grey boxes indicate patients that remain in the same risk group using 549	  
either histological or molecular categorization. 550	  
 551	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TABLE 1 Clinical characteristics of the non-metastatic cohort 
 
Histology ERMS 157 
 ARMS 53 
Median age at diagnosis (years)  4.5 
Age at dx <10 173 
 >=10 37 
IRS group 1 28 
 2 40 
 3 142 
Size of primary tumour <=5cm 90 
 >5cm 115 
 unknown 5 
Site of primary tumour Favourable 83 
 Unfavourable 127 
Median follow up time (years)  8.1 
Patient Survival Alive  151 
 Dead 59 
Total no of patients  210 
 
TABLE 2 Fusion gene status of the non-metastatic patient cohort, grouped by 
histology 	  
 ERMS ARMS Total 
Negative 156 20 176 
PAX3-FOXO1 1 27 28 
PAX7-FOXO1 0 6 6 
Total 157 53 210 	  
TABLE 3 Summary of changes in EpSSG risk group between histological and 
molecular categorization of pathology 
 
Risk 
Group 
Subgroup Histology Risk 
group 
Molecular Risk 
group 
% 
change 
Low A 9 10 +11.1 
Standard B  
70 
 
 
78 
 
+11.4 C 
D 
High E  
117 
 
113 
 
-3.4 F 
G 
Very High H 14 9 -35.7 	  
TABLE 4 Estimation of the number of patients needed for 80% power to 
detect decreased EFS rate in fusion gene negative alveolar patients with 
downgraded risk 
 
Change in EFS rate No of downgraded 
patients with ARMS FN  
Total patient number 
10% 141 2,015 
15% 63 900 
20% 36 515 
25% 23 329 
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Supplemental Table S1 Clinical and molecular characteristics of the 
metastatic cohort 
 
Histology ERMS 18 
 ARMS 32 
Median age at diagnosis (years)  8.2 
Fusion gene status ERMS Negative 18 
 ARMS Negative 8 
 PAX3-FOXO1 20 
 PAX7-FOXO1 4 
Median follow up time (years)  2 
Patient Survival Alive 10 
 Dead 40 
Total no of patients  50 	  
Supplemental Table S2 Risk Stratification for the EpSSG non-metastatic RMS study. 	  
Risk Group Subgroup Pathology IRS Group Site Node Stage Size & Age 
Low A Favourable I Any N0 Favourable 
Standard B Favourable I Any N0 Unfavourable 
C Favourable II, III Favourable N0 Any 
D Favourable II, III Unfavourable N0 Favourable 
High E Favourable II, III Unfavourable N0 Unfavourable 
F Favourable I, II, III Any N1 Any 
G Unfavourable I, II, III Any N0 Any 
Very High H Unfavourable I, II, III Any N1 Any 
Pathology: Favourable indicates embryonal histology including botryoid and spindle cell subtypes; Unfavourable indicates alveolar 
histology. Post surgical stage (IRS group): I indicates complete primary resection; II indicates microscopic residual or primary 
complete resection but N1; III indicates macroscopic residual. Site: Favourable indicates Orbit, Genitourinary (non 
bladder/prostate), Head and neck (non-parameningeal); Unfavourable indicates parameningeal, extremities, Genitourinary 
bladder/prostate and all other sites. Node Stage: N0 indicates no clinical or pathological node involvement; N1 indicates 
pathological node involvement. Size and Age: Favourable indicates tumour size less than or equal to 5 cm and age less than 10 
years; Unfavourable indicates all other options (i.e. Size greater than 5 cm and/or age greater than or equal to 10 years). 
Supplemental Table S3 Treatment protocol for EpSSG RMS risk groups 
 
Risk group 1st Course 2nd course Maintenance 
Low VA (8 cycles, 24 weeks) - - 
Standard (Subgroup B) IVA VA - 
Standard (Subgroup C) IVA IVA/No RT* - IVA/VA with RT - 
Standard (Subgroup D) IVA IVA with RT** - 
High IVA or IVADo*** IVA with RT** None or Vinorelbine/Cyclophosphamide (6 months)*** 
Very High IVADo IVADo/IVA** Vinorelbine/Cyclophosphamide (6 months) 
Tumour assessment carried out between first and second course of frontline therapy. VA = Vincristine/Actinomycin;  
IVA = Ifosfamide/Vincristine/Actinomycin; RT = radiotherapy; IVADo = Ifosfamide/Vincristine/Actinomycin/Doxorubicin 
*only given if patient shows complete response (CR) to first course and has favourable age and tumour size. 
**If patient shows stable disease (SD) after first course, second line treatment (usually Carboplatin, Cyclophosphamide, Topotecan 
or Doxorubicin) with radiotherapy will be given. 
***Randomised trial arms. 
Supplemental Table S4 Summary of changes in subgroup between histological and molecular categorization of pathology	  
	  
 Molecular Risk Group Total 
Low Standard High Very 
High 
A B C D E F G H  
 
 
 
Histology 
Risk 
Group 
Low A 9        9 
 
Standard 
B  11       11 
C   40      40 
D    19     19 
 
High 
E     57    57 
F      23   23 
G 1 2 3 3 6  22  37 
Very High H      5  9 14 
    Total 10 13 43 22 63 28 22 9 210 
% change (Hist. to Mol.) +11.1 +18.2 +7.5 +15.8 +10.8 +21.7 -40.5 -35.7  
Hist. = Histology; Mol. = Molecular. Note that grey boxes indicate patients that remain in the same risk group using either 
histological or molecular categorization. 
